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The role of MRI in the management of breast carcinoma is rapidly evolving from its initial use for speciﬁc indications only to a
more widespread use on all women with newly diagnosed early stage breast cancer. However, there are many concerns that such
widespread use is premature since detailed correlation of MRI ﬁndings with the underlying histopathology of the breast lesions
is still evolving and clear evidence for improvements in management and overall prognosis of breast cancer patients evaluated by
breast MRI after their initial cancer diagnosis is lacking. In this paper, we would like to bring attention to a benign lesion that is
frequently present on MRI-guided breast biopsies performed on suspicious MRI ﬁndings in the aﬀected breast of patients with a
new diagnosis of breast carcinoma.
1.Introduction
For patients with newly diagnosed breast carcinoma, evalua-
tion of the extent of the disease in the breast is of paramount
importance in planning appropriate surgical therapy. Mag-
netic resonance imaging (MRI) plays an ever increasing role
in the evaluation of additional areas in the aﬀected breast
deemed suspicious but indeterminate by other radiologic
modalities. Technical developments such as MRI with high
spatial resolution, special breast coils, dynamic kinetic
imaging techniques, and intravenous contrast agents con-
tribute to enhanced diagnosis of breast abnormalities. While
excitement about the role of this modality in improving the
planning of surgical treatment of breast cancer patients is
increasing [1–6], many areas of uncertainty remain, espe-
cially related to the clinical importance of additional lesions
that are detected by the use of MRI [7–9]. In this study we
evaluated the pathologic ﬁndings in MRI-guided needle core
biopsies of the breast obtained from other suspicious areas in
the aﬀected breast of patients with a new diagnosis of breast
carcinoma.
2.MaterialsandMethods
Our study population consisted of 44 MRI-guided needle
core breast biopsies performed on 40 patients with newly
diagnosed breast carcinoma at Rush University Medical
Center, Chicago, IL, USA between May 2007 and July 2008.
Histologic ﬁndings of these biopsies were reviewed and
recorded. Patient age ranged from 36 to 77 years (average:
52 years).
3. Results
Overall, 9/44 (20.4%) of our MRI-guided breast biop-
sies were malignant, 29/44 (66%) were benign, and 6/44
(13.6%) showed atypia (Table 1). Of the 9 malignant cases,
4 were inﬁltrating ductal carcinomas with tubular features,
2 inﬁltrating lobular carcinomas, and 3 ductal carcinoma
in situ lesions (Table 2). Of the 6 atypical cases, 2 were
atypical ductal hyperplasia (ADH), 2 were atypical lobular
hyperplasia (ALH), and 2 showed areas of columnar cell
hyperplasia with atypia (Table 3). Of interest, more than one2 International Journal of Breast Cancer
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Figure 1: Representative examples of MRI-guided breast needle core biopsies showing a characteristic benign complex multicystic lesion
lined by apocrine metaplastic epithelium, called “cystic apocrine metaplasia.” This benign lesion was seen in 38% (11/29) of the benign
MRI-guided needle core biopsies in this series.
Table 1: Histologic ﬁndings of MRI-guided needle core biopsies.
Histology No. of patients (n = 44)
Malignant 9 (20.4%)
Atypical 6 (13.6%)
Benign 29 (66%)
Table 2: Histologic ﬁndings of MRI-guided needle core biopsies
that showed malignancy.
Malignant histology No. of patients (n = 9)
IDC 4
ILC 2
DCIS 3
Table 3: Histologic ﬁndings of MRI-guided needle core biopsies
that showed atypia.
Atypical histology No. of patients (n = 6)
ADH 2
ALH 2
CCH with atypia 2
third of our benign cases (11/29, 38%) consisted of a speciﬁc
complex multicystic lesion lined by apocrine metaplastic
epithelium, a lesion we called “cystic apocrine metaplasia”
(Figure 1).
4. Discussion
During the last few years there has been a heightened
interest in the application of magnetic resonance imaging
(MRI) in the management of breast cancer. Currently, MRI
is used as a supplemental tool to complement conven-
tional methods of radiologic and ultrasonographic breast
evaluation. A number of appropriate indications for the
clinical use of MRI in breast cancer diagnosis and man-
agement include clariﬁcation of questionable ﬁndings on
mammography, evaluation and accurate staging of breast
tumors in dense breasts, accurate evaluation of speciﬁc
subtypes of breast carcinomas such as inﬁltrating lob-
ular carcinoma, assessment of response to preoperative
chemotherapy, diagnosis of occult primary breast tumors
presenting with axillary nodal involvement, and surveil-
lance programs assessing high-risk patients such as breast
cancer gene carriers or patients with a history of chest
irradiation [1–6].
However, as the use of MRI at the time of new diagnosis
of early stage breast cancer is quickly becoming a new
standard of care, there is heightened concern that routine
use of MRI for preoperative staging may lead to more
extensive surgery, while solid evidence for improvement
of surgical management, improved rates of local con-
trol, or improved overall prognosis is lacking [8–12]. In
addition, while in a number of studies the detection of
additional foci of breast cancer by MRI in the aﬀected breast
is reported to be around 16% (ranging from 6 to 34%)
[12, 13], only limited information exists on the histology of
the additional lesions that MRI testing falsely identiﬁes as
worrisome [14].
In this paper, we report that MRI-guided needle core
biopsies of separate lesions in the aﬀected breast of patients
with newly diagnosed breast carcinoma show additional
foci of malignancy in 20% of cases. A high percentage
(66%) of these additional suspicious areas by MRI are
benign by histologic examination. More speciﬁcally, MRI-
guided needle core biopsies seem to target a characteristic
complex multicystic lesion lined by apocrine metaplastic
epithelium, in over one third of the cases, a lesion we
called “cystic apocrine metaplasia.” Our ﬁndings suggest that
MRI-guided core biopsies result in an important change of
detection of additional foci of malignancy in a signiﬁcant
number of cases. In addition, MRI-directed needle core
biopsies often target benign lesions with speciﬁc histopatho-
logic characteristics, namely, a characteristic complex mul-
ticystic lesion lined by apocrine epithelium, the so-called
“cystic apocrine metaplasia.” We suggest that awareness ofInternational Journal of Breast Cancer 3
the correlation of this benign lesion with abnormal MRI
ﬁndings by radiologists will be helpful as they evaluate breast
MRI studies of patients with newly diagnosed early stage
breast carcinoma.
Ongoing carefully controlled studies comparing the
strengths and weaknesses of breast MRI to those of con-
ventional breast imaging in diﬀerent clinical scenarios, as
well as detailed correlation of MRI ﬁndings to underlying
histopathology ofbreastlesions, areurgentlyneeded inorder
to clearly deﬁne diagnostic criteria for widespread MRI use.
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